We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-7.92%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$443M
AUM Growth
-$5.44M
Cap. Flow
-$82.1M
Cap. Flow %
-18.51%
Top 10 Hldgs %
47.3%
Holding
81
New
8
Increased
12
Reduced
20
Closed
11

Top Buys

Rank Stock Value
1
NVAX icon
Novavax
NVAX
+$11.8M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$8.15M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$6.61M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$6.34M
5
UTHR icon
United Therapeutics
UTHR
+$3.81M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$17.9M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$13.7M
3
GILD icon
Gilead Sciences
GILD
+$12.4M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$12.4M
5
BIIB icon
Biogen
BIIB
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.53%
2 Miscellaneous 0.47%
3 Utilities 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DYN icon
51
Dyne Therapeutics
DYN
$4.87B
$1.16M 0.26%
476,000
– –
KRYS icon
52
Krystal Biotech
KRYS
$10.6B
$1.11M 0.25%
45,000
– –
FOLD
53
DELISTED
Amicus Therapeutics
FOLD
$1.09M 0.25%
94,600
– –
GILD icon
54
Gilead Sciences
GILD
$185B
$1.08M 0.24%
88,784
-194,000
-69% -$12.4M
ORIC icon
55
Oric Pharmaceuticals
ORIC
$1.42B
$905K 0.2%
176,217
+23,217
+15% +$209K
BPMC
56
DELISTED
Blueprint Medicines
BPMC
$881K 0.2%
19,500
– –
IMVT icon
57
Immunovant
IMVT
$9.05B
$851K 0.19%
60,000
– –
FULC icon
58
Fulcrum Therapeutics
FULC
$294M
$833K 0.19%
82,741
+21,741
+36% +$308K
ALLO icon
59
Allogene Therapeutics
ALLO
$722M
$747K 0.17%
50,000
– –
RLMD icon
60
Relmada Therapeutics
RLMD
$482M
$741K 0.17%
10,000
– –
AGIO icon
61
Agios Pharmaceuticals
AGIO
$2.05B
$707K 0.16%
21,500
– –
PTCT icon
62
PTC Therapeutics
PTCT
$5.99B
$617K 0.14%
411,000
-38,000
-8% -$1.46M
NTLA icon
63
Intellia Therapeutics
NTLA
$1.84B
$511K 0.12%
24,000
– –
ANAB icon
64
AnaptysBio
ANAB
$1.7B
$348K 0.08%
10,000
– –
GH icon
65
Guardant Health
GH
$22.6B
$271K 0.06%
74,500
– –
BMRN icon
66
BioMarin Pharmaceuticals
BMRN
$12.6B
$235K 0.05%
79,656
-25,500
-24% -$2.13M
SGEN
67
DELISTED
Seagen Inc. Common Stock
SGEN
$225K 0.05%
76,200
-37,000
-33% -$5.01M
NKTX icon
68
Nkarta
NKTX
$197M
$209K 0.05%
10,034
-30,166
-75% -$323K
TSVT
69
DELISTED
2seventy bio
TSVT
$94K 0.02%
3,666
– –
BBIO icon
70
BridgeBio Pharma
BBIO
$15.4B
– –
-52,800
Closed -$881K
BDTX icon
71
Black Diamond Therapeutics
BDTX
$130M
– –
-44,000
Closed -$235K
BIIB icon
72
Biogen
BIIB
$32.7B
– –
-47,500
Closed -$11.4M
CRSP icon
73
CRISPR Therapeutics
CRSP
$5.74B
– –
-108,200
Closed -$8.19M
EXAS
74
DELISTED
Exact Sciences
EXAS
– –
-10,700
Closed -$833K
EXC icon
75
Exelon
EXC
$45.3B
– –
-766,241
Closed -$9.98M
1 2
3
4

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q1 2022 Portfolio in Review

As of Q1 2022, International Biotechnology Trust held 81 positions worth $443M, down 1.2% from $449M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

International Biotechnology Trust withdrew a net $82.1M in Q1 2022, closing 11 positions and reducing 20 holdings. Its most notable exit was Biogen, an estimated $11.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Miscellaneous and Utilities.

Against the trend, International Biotechnology Trust opened a new position in Novavax worth $18.5M.

  • International Biotechnology Trust's largest Q1 2022 buy was Novavax: 132,500 shares worth $18.5M.
  • International Biotechnology Trust added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2022, an estimated $8.15M increase.
  • International Biotechnology Trust's biggest Q1 2022 reduction was Amgen, cutting an estimated $17.9M.
  • International Biotechnology Trust fully exited Biogen in Q1 2022, selling an estimated $11.4M.
  • International Biotechnology Trust's ten largest holdings make up 47% of its $443M portfolio in Q1 2022.
  • International Biotechnology Trust opened 8 new positions and closed 11 in Q1 2022.
  • International Biotechnology Trust's portfolio value fell 1.2% quarter-over-quarter to $443M.

Based on International Biotechnology Trust's 13F filing for Q1 2022, filed 20 May 2022.